Physicians' Academy for Cardiovascular Education
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the increased risk from apoB-containing lipoproteins to MI, and triglycerides in VLDL explain 0%. With poll.
This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.
EAS 2020 In participants of the UK Biobank, a LPA genetic risk score and measured Lp(a) levels provided comparable risk prediction for ASCVD risk in a primary prevention setting.
EAS 2020 Inhibition of ANGPTL3 with evinacumab reduced LDL-c levels significantly in HoFH patients with little to no LDL receptor function.
EAS 2020 A subanalysis of ORION-9 showed that lowering of LDL-c by inclisiran was similar across subgroups of genotypes in those with heterozygous FH.
EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.
ESC 2020 The EVAPORATE trial showed that icosapent ethyl 4g/day, compared with placebo, significantly reduced multiple plaque components in patients with elevated triglycerides on statin therapy
This trial in 57 patients with non-STEMI and troponin I ≥5 ng/mL showed that more patients reach LDL-c targets at hospital discharge with evolocumab plus high-intensity statin therapy compared with placebo plus high-intensity statin therapy.
